度普利尤单抗治疗中国中重度特应性皮炎的随机双盲安慰剂对照研究
该研究为随机双盲安慰剂对照III期试验,纳入165例中国成人中重度特应性皮炎患者,评估度普利尤单抗(300mg每2周)16周疗效与安全性。
要点
- 治疗期不良事件发生率两组相似,但结膜炎和注射部位反应更常见。
核心结论
- 在中国成人中重度特应性皮炎患者中,度普利尤单抗可有效改善皮损和瘙痒症状,且安全性良好。
研究设计与样本
- 随机、双盲、安慰剂对照、平行分组III期研究,2018年12月至2020年2月进行。
- 共纳入165例成人中重度特应性皮炎患者,度普利尤单抗组82例,安慰剂组83例。
- 度普利尤单抗300mg或安慰剂每2周一次,治疗16周,随访12周。
主要发现
- 治疗期不良事件发生率两组相似,但度普利尤单抗组结膜炎、过敏性结膜炎和注射部位反应发生率高于安慰剂组。
临床怎么用
- 度普利尤单抗可作为中国成人中重度特应性皮炎的有效治疗选择,需关注结膜炎和注射部位反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab is an antibody against interleukin-4 receptor α, used in the treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of dupilumab in adult Chinese patients with moderate-to-severe AD. METHODS: In this randomized, double-blind, placebo-controlled, parallel-group, phase III study, conducted between December 2018 and February 2020, patients with AD received dupilumab (300 mg) or placebo once every 2 weeks for 16 weeks, and were followed up for 12 weeks. The primary efficacy endpoint was the proportion of patients with both an Investigator's Global Assessment score of 0-1 and a reduction from baseline of ≥ 2 points at week 16. RESULTS: Overall, 165 patients (mean age 30·6 years; 71·5% male patients) were randomized; 82 patients were randomized to dupilumab and 83 patients were randomized to placebo. At week 16, 26·8% of patients in the dupilumab group and 4·8% of patients in the placebo group achieved the primary endpoint [difference 22·0%, 95% confidence interval (CI) 11·37-32·65; P < 0·001]. Compared with placebo, higher proportions of patients in the dupilumab group achieved ≥ 75% reduction in the Eczema Area and Severity Index score (57·3% vs. 14·5%; difference 42·9%, 95% CI 29·75-55·97; P < 0·001) and had ≥ 3-point (52·4% vs. 9·6%; difference 42·8%, 95% CI 30·26-55·34; P < 0·001) and ≥ 4-point (39·0% vs. 4·8%; difference 34·2%, 95% CI 22·69-45·72; P < 0·001) reductions in weekly average daily peak daily pruritus numerical rating scale scores. The incidence of treatment-emergent adverse events during the treatment period was similar in the two groups. The incidence of conjunctivitis, allergic conjunctivitis and injection site reaction was higher in the dupilumab group than in the placebo group. CONCLUSIONS: In adult Chinese patients, dupilumab was effective in improving the signs and symptoms of AD and demonstrated a favourable safety profile.
引用
- Zhao Y, Wu L, Lu Q, et al. The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2021. PMID: 34358343. doi:10.1111/bjd.20690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。